spec sheet7 rows
Atrimustine is an investigational cytostatic antineoplastic agent developed in Japan, structurally an estradiol molecule conjugated to the nitrogen mustard chlorambucil. It was studied for breast cancer, non-Hodgkin lymphoma, and prevention of graft-versus-host disease after bone marrow transplant, but never reached full marketing approval.
- Site-directed cytotoxic design intended to concentrate chemotherapy in estrogen receptor-positive tissue
- Studied across multiple indications: breast cancer, non-Hodgkin lymphoma, and graft-versus-host disease prevention
- Reached preregistration stage in Japan before development stalled
- Estrogenic side effects reported, including vaginal bleeding and gynecomastia
Overview
Same design idea as the approved drug estramustine: pair a hormone carrier with an alkylating agent to steer chemotherapy toward hormone-sensitive tissue.
Mechanism
The estradiol portion of atrimustine binds receptors, concentrating the molecule in estrogen receptor-positive tissue such as breast and bone. The conjugated chlorambucil portion is a nitrogen mustard alkylating agent that cross-links DNA strands, triggering cell death in rapidly dividing cells. This design aims for site-directed cytotoxicity in hormone-sensitive tumors, a concept shared with the related, more established drug estramustine.
receptor fingerprint
DNA (via nitrogen mustard alkylation)Inhibitor
receptorSubstrate
Safetyrisks and cautions, not medical advice
Reported clinical experience noted estrogenic side effects, including vaginal bleeding and gynecomastia, consistent with its estradiol-based structure. It reached the preregistration stage in Japan but was ultimately not brought to market, and detailed modern safety data are not publicly available.
Subjective profileweighing the evidence above
A neat piece of drug design that stalled at preregistration in Japan and stayed there. Estrogenic effects including gynecomastia and vaginal bleeding were reported, modern safety data does not exist, and it is chemotherapy regardless; nothing about it belongs outside a clinic.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Atrimustine used for?
It was developed in Japan as a chemotherapy candidate for breast cancer and non-Hodgkin lymphoma, and to help prevent graft-versus-host disease after bone marrow transplant.
How does Atrimustine work?
It links an estrogen molecule to a nitrogen mustard chemotherapy agent; the estrogen part helps target hormone-sensitive tissue, and the mustard part cross-links DNA to kill cancer cells.
Is Atrimustine well-researched?
It reached the preregistration stage in Japan with documented clinical use, but detailed modern trial data and safety records are not publicly accessible.
Limitations of the evidence
- Modern, detailed safety data are not publicly available
Adverse effects
- Estrogenic side effects reported, including vaginal bleeding and gynecomastia
Notes and cautions
- Never received full marketing approval